The KANK1 Knockout A-549 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma line, engineered to disrupt the KANK1 gene. This polyclonal pool offers a heterogeneous loss-of-function model for studying KANK1-dependent processes without clonal selection bias. The cells are designed for downstream investigations into tumor suppression, cytoskeletal regulation, and focal adhesion biology in a relevant epithelial context.
The host A-549 cell line, originally isolated from a 58-year-old Caucasian male with lung adenocarcinoma, serves as a widely utilized model for human alveolar type II pulmonary epithelium. These adherent epithelial cells exhibit characteristics of lung carcinoma, including constitutive activation of signaling pathways relevant to cancer progression. Their widespread use in respiratory research and oncology makes them an appropriate background for interrogating KANK1 function in a disease-relevant setting.
KANK1 functions as a scaffolding protein that bridges integrin-mediated adhesion to dynamic actin cytoskeleton remodeling. It recruits the cortical microtubule-stabilizing complex to focal adhesions, where it interacts with talin-1 (TLN1) and other partners such as PPFIBP1, YWHAZ, and PHLDB2 to negatively regulate RhoA signaling. Under physiological conditions, KANK1 suppresses RhoA activity, reducing ROCK-dependent actomyosin contractility and phosphorylation of myosin light chain. This pathway converges on the inhibition of SRF/MAL transcriptional activity and stabilization of focal adhesions via factors like vinculin (VCL) and PTK2. Upstream regulators including TGFB1, p53, and AKT1 modulate KANK1 expression, while downstream effectors involve attenuation of integrin ??1 (ITGB1) and ??3 (ITGB3) downstream signaling cascades.
In the context of lung adenocarcinoma, loss of KANK1 function is associated with enhanced cell migration, invasion, and metastatic potential. The A-549 polyclonal knockout model provides a controlled system to delineate the contribution of KANK1 to these malignant phenotypes. By disrupting KANK1, researchers can examine the consequent activation of RhoA/ROCK signaling and its impact on actin stress fiber formation, focal adhesion turnover, and cellular contractility. This model is particularly suited for dissecting tumor suppressor mechanisms in an epithelial background that recapitulates important features of non-small cell lung cancer.
Typical applications include western blotting for KANK1, RhoA-GTP, and phosphorylated MLC to validate pathway activation; immunofluorescence visualization of actin architecture and focal adhesion components; and transwell migration/invasion assays to quantify phenotypic changes. The cells can be employed in RhoA activation G-LISA, cell adhesion studies, colony formation assays, and xenograft tumor growth models to evaluate anti-metastatic compound effects. For additional information regarding this product, please contact Ascent Research.
